TREATMENT PATHWAY FOR THE MANAGEMENT OF ADULTS with MODERATE to SEVERE ECZEMA in SECONDARY CARE.




(FOR SPECIALIST INITIATION ONLY)

TARGET AUDIENCE	All clinical staff working within Dermatology in secondary care.
PATIENT GROUP	Adults with Moderate to Severe Atopic Eczema AND Inadequate repsonse to or contraindication to ciclosporin/methotrexate/ azathioprine/mycophenolate mofetil

Clinical Guidelines Summary

- This guideline describes the pathway for management of adult patients with moderate to severe atopic eczema and had an inadequate response to or contraindication to ciclosporin/methotrexate/ azathioprine/mycophenolate mofetil.
- The pathway provides a stepwise approach to the management of Atopic Eczema with biologic therapy (IL-4/IL-13 or IL-13 inhibitors) or JAK2 inhibitors (JAKi) by Dermatology Specialists in secondary care only.
- The pathway includes drug prescribing guidance for the use of biologics and JAKis in Atopic Eczema.





Only use if no suitable alternative in patients

- >65years
- Increased risk of CV events
- Smokers/previous smoker for long duration
- Increased risk of cancer

Adequate response is defined as:

at least 50% reduction in EASI score and

• Discontinue if response is not adequate at the review

at least a 4 point reduction in DLQI

date or there is loss of response

Lead Author	Carole Martin	Date approved	18/10/2023
Version	1.0	Review Date	18/10/2025



Prescribing Notes:

Prescreening:

- Screen for TB, viral hepatitis, HIV and VZV serology prior to commencing JAKi or biologic.
- Baseline U&Es, LFTs, FBC should be checked.
- > Baseline lipids and CK should be checked prior to commencing JAKi.

Drug interactions with JAKi:

Prior to initiation of a JAKi, all patients must have a review by the dermatology pharmacist of their current medications to check for any significant drug interactions.

Cautions with JAKi:

Use JAKi with caution in patients with:

- High risk of DVT/PE Risk factors include older age, obesity, history of DVT/PE, undergoing major surgery, prolonged immbolisation. Patients should be informed of the signs and symptoms of VTE before starting treatment and advised to seek urgent medical attention if these develop.
- > Aged 65 years and above
- Increased risk of CV events
- Current smokers and previous long term smokers
- Increased risk of cancer.

Ocular Side Effects with Dupilumab:

- Discuss with the patient the possibility of ocular side effects and the symptoms to look out for when initiating Dupilumab.
- Encourage all patient to use prophylactic eye lubricants Use formulary choice of lubricating eye drops (4 times per day for 2 weeks prior to starting Dupilumab).
- Advise patients to report new-onset or worsening eye symptoms to a healthcare professional/optician.
- Promptly review new-onset/worsening ocular symptoms/changes in vision/eye pain that does not settle and refer to ophthalmologist.

Vaccinations:

- Annual flu/Covid vaccines recommended.
- Pneumococcal vaccination 2- 4 weeks before initiation. Only repeat after 5 years if asplenic/splenic dysfunction or Chronic Kidney Disease Stage 4 or 5 (will also require Hep B vaccination).
- Check VZV serology prior to commencing and refer for vaccination if required.

Transfer of Information to Primary Care:

Drug name (Biosimilar or equivalent) and dosing schedule should be documented in clinic letter for GP so ECS can be updated appropriately.

Lead Author	Carole Martin	Date approved	18/10/2023
Version	1.0	Review Date	18/10/2025



Dosing:

Druce	Data	
Drug	Dose	Additional Information
Abrocitinib (JAKi)	Adults:	Check Baseline U&Es, LFTs, FBC, Lipids,
	200mg once daily	at Week 4 and then 6 monthly.
	≥65 yrs or at risk of adverse	Reduce initial dose to 50mg daily in
	reaction/less liklely to tolerate:	severe renal impairment (max 100mg
	100mg once daily	daily)
		Reduce dose by half in moderate renal
	Dose may be adjusted based on	impairment (eGFR 30-60ml/min) i.e
	tolerability and efficacy	50mg or 100mg daily.
	tolerubility and emedey	
		Avoid if severe hepatic impairment.
Upadacitinib (JAKi)	Adults:	Check Baseline U&Es, LFTs, FBC, Lipids,
	30mg once daily if high disease	at Week 12 and then 6 monthly.
	burden/inadequate response to	
	15mg.	Reduce dose to 15mg daily in severe
		renal impairment.
	≥65 yrs/ or at risk of adverse	
	reaction: 15mg daily	Avoid if severe hepatic impairment.
	Dose may be adjusted based on	
	tolerability and efficacy	
Dupilumab (IL-4/IL- 13	Adults:	Checks U&Es, LFTs, FBC at baseline, 16
inhibitor)	Initially 600mg s/c, then 300mg	week review and then 6 monthly.
	every 2 weeks.	
Baricitinib (JAKi)	Adults:	Check Baseline U&Es, LFTs, FBC, Lipids,
	4mg once daily	at Week 12 and then 6 monthly.
	2mg once daily if ≥75years	
		Reduce dose to 2mg daily if CrCl =30-
		60ml/min
		Avoid if CrCl<30ml/min
		Avoid if severe hepatic impairment.
Tralokinumab (IL-13	Adults:	Checks U&Es, LFTs, FBC at baseline, 16
inhibitor)	Initially 600mg s/c, then 300mg	week review and then 6 monthly.
	every 2 weeks.	
	Patients who achieve clear/almost	
	clear skin after Week 16 can reduce	
	to 300mg every 4 weeks. This may	
	not be appropriate in patients	
	>100kg.	

Abbreviations:

JAKi – Janus Kinase Inhibitor, DLQI – Dermatology Life Quality Index, EASI – Eczema Area and Severity Index. POEM – Patient-orientated eczema measures.

Lead Author	Carole Martin	Date approved	18/10/2023
Version	1.0	Review Date	18/10/2025



Appendices

1. Governance information for Guidance document

Lead Author(s):	Carole Martin, Lead Pharmacist for Dermatology, NHS Lanarkshire
Endorsing Body:	Dermatology Consultants and Specialist doctors.
Version Number:	1.0
Approval date	18/10/2023
Review Date:	18/10/2025
Responsible Person (if different from lead author)	n/a

CONSULTATION AND DISTRIBUTION RECORD				
Contributing Author / Authors	Dr. Freida Shaffrali, Dermatology Consultant, NHSL Dr.Helen Dilworth, Dermatology Consultant, NHSL Dr.Rakhee Gupta, Speciality Doctor, Dermatology			
Consultation Process / Stakeholders:	Consultants and Specialist Dermatology Doctors NHSL			

Lead Author	Carole Martin	Date approved	18/10/2023
Version	1.0	Review Date	18/10/2025



Distributio	n	Consultants and Specialist Dermatolo Specialist Dermatology Pharmacist Heads of Pharmacy, NHSL Homecare Medicines Services, NHSI	
CHANGE R		Change	Version No.
CHANGE R Date Dct 2023	ECORD Lead Author Carole Martin	Change Initial version	Version No.
Date	Lead Author	Change Initial version	
Date	Lead Author	Change Initial version	1
Date	Lead Author	Initial version	1 2 3
Date	Lead Author	Change Initial version	1 2 3 4
Date	Lead Author	Initial version	1 2 3

Lead Author	Carole Martin	Date approved	18/10/2023
Version	1.0	Review Date	18/10/2025